All prescription sales are final
FDA indications According to the Prescribing Information, the wording of the FDA indications for semaglutide injection (Wegovy ) is as follows (the emphasis below in red has been added by us): WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
The FDA is also evaluating reports of intestinal obstruction from Mounjaro, Ozempic, and other GLP-1 receptor agonists
If its been a few months, talk to your healthcare provider
Brand-Name Semaglutide FDA-approved (e.g., Wegovy, Ozempic) Standardized formulation with fixed dosing options Available only through a pharmacy Ideal for patients whose insurance covers brand-name prescriptions Compounded Semaglutide Custom-prepared by licensed compounding pharmacies Can be enhanced with supportive ingredients like L-Carnitine, which helps convert stored fat into energy, boosts metabolism, and supports exercise endurance Allows for more individualized dosing and adjustments, making it a better fit for patients who cannot tolerate brand-name semaglutide or want a more tailored approach Shipped directly to patients following provider approval How Treatment Works Regardless of which option you choose, treatment begins with a comprehensive consultation to determine candidacy
.jpg)
